Valuation: Xencor, Inc.

Market Cap 1.18B 1.03B 948M 876M 1.66B 112B 1.69B 11.33B 4.45B 55.21B 4.41B 4.32B 190B P/E 2026 *
-4.07x
P/E 2027 * -4.92x
Enterprise Value 1.18B 1.03B 948M 876M 1.66B 112B 1.69B 11.33B 4.45B 55.21B 4.41B 4.32B 190B EV / Sales 2026 *
16.6x
EV / Sales 2027 * 10.6x
Free-Float
98.82%
Yield 2026 *
-
Yield 2027 * -
1 day-1.64%
1 week+5.67%
Current month-1.55%
1 month+28.55%
3 months+27.62%
6 months+11.86%
Current year+3.53%
1 week 14.72
Extreme 14.725
16.98
1 month 11.9
Extreme 11.9
16.98
Current year 10.38
Extreme 10.375
16.98
1 year 6.92
Extreme 6.92
18.69
3 years 6.92
Extreme 6.92
27.24
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 01/02/2005
Director of Finance/CFO 48 09/04/2024
Chief Tech/Sci/R&D Officer 61 01/10/2006
Director TitleAgeSince
Director/Board Member 55 01/08/1997
Director/Board Member 58 25/07/2014
Director/Board Member 72 18/03/2015
Date Insider Type Main position Quantity % Market Cap.
06-18Sell

Director

-6,843 0.0092%
06-16Free

Director

30,906 0.0417%
06-16Free

Director

30,906 0.0417%
Change 5-day change 1-year change 3-year change Capi.($)
-1.64%+5.67%+79.50%-32.57% 1.18B
+1.84%-0.66%+59.82%+94.48% 54.88B
+0.73%-5.36%+57.86%+131.26% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+0.58%+2.65%+36.73%-27.48% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -1.43%+0.32%+54.03%+180.26% 24.27B
Weighted average by Cap. -0.59%-1.42%+50.68%+172.23%

Financials

2026 *2027 *
Net sales 70.58M 61.74M 56.94M 52.59M 99.79M 6.73B 101M 680M 267M 3.32B 265M 259M 11.4B 110M 96.61M 89.11M 82.3M 156M 10.53B 159M 1.06B 418M 5.19B 415M 406M 17.84B
Net income -309M -271M -250M -231M -438M -29.51B -445M -2.98B -1.17B -14.54B -1.16B -1.14B -49.98B -288M -252M -232M -215M -407M -27.46B -414M -2.78B -1.09B -13.53B -1.08B -1.06B -46.5B
Net Debt - -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
10/07/26 $15.85 -1.64% 544,665
09/07/26 $16.12 -2.10% 1,478,030
08/07/26 $16.46 +5.04% 1,164,151
07/07/26 $15.67 +5.24% 719,118
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.85USD
Average target price
28.33USD
Spread / Average Target
+78.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock